144 related articles for article (PubMed ID: 31697814)
1. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
2. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
Ngu HS; Savage KJ
Haematologica; 2023 Dec; 108(12):3211-3226. PubMed ID: 38037799
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.
Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A
Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886
[TBL] [Abstract][Full Text] [Related]
5. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis.
Tonozuka Y; Tanaka H; Nomura K; Sakaguchi K; Soeda J; Kakimoto Y
Cancer Chemother Pharmacol; 2024 Feb; 93(2):137-149. PubMed ID: 37921901
[TBL] [Abstract][Full Text] [Related]
6. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
Kaimi Y; Takahashi Y; Taniguchi H; Ochi T; Makino H; Makita S; Iwaki N; Fukuhara S; Munakata W; Ogawa C; Izutsu K; Maeshima AM
Virchows Arch; 2024 Mar; 484(3):465-473. PubMed ID: 38349387
[TBL] [Abstract][Full Text] [Related]
7. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas.
Burton JS; Foley NC; Mehta-Shah N
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):65-76. PubMed ID: 37973458
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-driven management strategies for peripheral T cell lymphoma.
Mulvey E; Ruan J
J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
[TBL] [Abstract][Full Text] [Related]
9. A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.
Kelly KA; Edenfield L; Seegars MB; Vaidya R; Feldman SR; Strowd LC
J Drugs Dermatol; 2023 Dec; 22(12):e33-e34. PubMed ID: 38051830
[TBL] [Abstract][Full Text] [Related]
10. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN
Br J Cancer; 2020 Sep; 123(7):1101-1113. PubMed ID: 32684628
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity.
Heiser RA; Cao AT; Zeng W; Ulrich M; Younan P; Anderson ME; Trueblood ES; Jonas M; Thurman R; Law CL; Gardai SJ
Mol Cancer Ther; 2024 Jan; 23(1):68-83. PubMed ID: 37775098
[TBL] [Abstract][Full Text] [Related]
12. The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.
Boddicker RL; Kip NS; Xing X; Zeng Y; Yang ZZ; Lee JH; Almada LL; Elsawa SF; Knudson RA; Law ME; Ketterling RP; Cunningham JM; Wu Y; Maurer MJ; O'Byrne MM; Cerhan JR; Slager SL; Link BK; Porcher JC; Grote DM; Jelinek DF; Dogan A; Ansell SM; Fernandez-Zapico ME; Feldman AL
Blood; 2015 May; 125(20):3118-27. PubMed ID: 25833963
[TBL] [Abstract][Full Text] [Related]
13. Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5106.
Blood Adv; 2024 May; 8(9):2243. PubMed ID: 38743412
[No Abstract] [Full Text] [Related]
14. Emerging strategies in peripheral T-cell lymphoma.
Mehta-Shah N
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):41-46. PubMed ID: 31808829
[TBL] [Abstract][Full Text] [Related]
15. Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
Ong SY; Zain JM
Am J Hematol; 2024 Mar; 99(3):439-456. PubMed ID: 38304959
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of BCL11b and CDKN2A in CD30-positive peripheral T cell lymphoma: Retrospective study.
Wang Y; Zhang F; Gao N; Bu P; Cui W; Xi Y
Medicine (Baltimore); 2023 Nov; 102(46):e35531. PubMed ID: 37986346
[TBL] [Abstract][Full Text] [Related]
17. Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression.
Sarwar S; Tome ME; Billheimer D; Spier C; Smith CL; Persky D; Schmelz M
Histol Histopathol; 2024 Mar; 39(3):319-331. PubMed ID: 37377225
[TBL] [Abstract][Full Text] [Related]
18. Mycosis fungoides: successful re-treatment with brentuximab vedotin.
James M; Nakamura M; Whittaker S; Morris S
Br J Dermatol; 2024 May; 190(6):929-930. PubMed ID: 38470968
[No Abstract] [Full Text] [Related]
19. Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs).
Moskowitz AJ; Stuver RN; Horwitz SM
Blood; 2024 Feb; ():. PubMed ID: 38306597
[TBL] [Abstract][Full Text] [Related]
20. Novel targeted therapies of T cell lymphomas.
Iżykowska K; Rassek K; Korsak D; Przybylski GK
J Hematol Oncol; 2020 Dec; 13(1):176. PubMed ID: 33384022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
